Oridonin has been shown to exhibit therapeutic effects against hepatocellular carcinoma (HCC) in vitro and in vivo. This study aimed to identify the anti-HCC mechanisms of oridonin in HepG2 cells using proteomic and functional analyses. MTT assay showed that oridonin treatment for 24 hours dose-dependently inhibited cell growth with an IC 50 value of 40.4 mM. Treatment with 40 mM oridonin for 24 hours induced apoptosis determined by nuclear morphologic changes of DAPI-stained cells and flow cytometric analysis of annexin V-FITC/PI-stained cells, which was accompanied by Grp78 upregulation and a-CP1 downregulation identified by proteomic analysis. Immunoblot analysis for the endoplasmic reticulum (ER) stressrelated proteins demonstrated that the expression levels of phosphorylated PERK (p-PERK) and CHOP were increased, whereas PERK, ATF-6, and IRE-1 expression levels were decreased. Knockdown of a-CP1 expression with siRNA significantly increased cell death and apoptosis in control and oridonin-treated HepG2 cells. Together, these data provide proteomic and functional evidence for the potential involvement of ER stress and a-CP1 in the antiproliferative and apoptotic activities of oridonin in HepG2 cells, which shed new light on the action mechanisms of oridonin in HCC management.
Introduction
Rabdosia rubescens (Hemsl.) C.Y. Wu et Hsuan (Lamiaceae), a folk medicinal herb that grows mainly in the Yellow River area in China, has been used to treat stomachache, pharyngitis, sore throat, cough, as well as esophageal, gastric cardia, breast, prostate, and liver cancers. 1 Oridonin is the major bioactive constituent of R rubescens and exhibits therapeutic effect against tumors such as esophageal and hepatocellular carcinoma (HCC) in clinical trials. 2 In experimental animals, oridonin inhibits the growth of Ehrlich-Ascites tumor, sarcoma 180, esophageal carcinoma, and hepatoma. 1 Oridonin shows anticancer effects on various cancer cells, such as breast carcinoma, lung cancer, prostate carcinoma, cervical carcinoma, gastric cancer, leukemia, laryngeal carcinoma, melanoma, and hepatoma 3-10 by inhibiting angiogenesis, cell migration and proliferation, 11, 12 and inducing apoptosis, autophagy, and differentiation. 4, 8, 12 In hepatoma cells, telomerase inhibition, generation of reactive oxygen species (ROS), as well as activation of p53 and caspases has been implicated in the apoptotic activity of oridonin 9, 10 ; in this study, we discovered that endoplasmic reticulum (ER) stress and a heterogeneous nuclear ribonucleoprotein, a-CP1, were potentially involved in the antiproliferative and apoptotic activities of oridonin in HepG2 cells.
Materials and Methods

Reagents and Antibodies
Oridonin (Figure 1 ) was purchased from Shanghai Shamrock Imp & Exp Trading Co. Ltd, and the purity was determined to be 97% by HPLC. MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was obtained from USB Corporation (Cleveland, OH). 4,6-Diamidino-2-phenylindole (DAPI) was from Sigma-Aldrich Bio technology (St Louis, MO). Annexin V-FITC Apoptosis Detection Kit I was obtained from BD Bioscience (San Jose, CA). Protease inhibitor cocktail and phosphatase inhibitor cocktail were from Roche Bioscience (Palo Alto, CA). Bio-Rad Protein Assay was from Bio-Rad Laboratories, Inc (Hercules, CA). Nitrocellulose membrane, ECL detection reagents, and iodoacetamide (IAA) were from Amersham Biosciences (Piscataway, NJ). Grp78, PERK, IRE-1, and CHOP antibodies were from Cell Signaling Technology (Danvers, MA); a-CP1, p-PERK (Thr981), ATF-6, b-actin, and anti-rabbit IgG (horseradish peroxidase conjugated) antibodies, as well as a-CP1 siRNA and control siRNA were from Santa Cruz Biotechnology (Santa Cruz, CA); anti-mouse IgG antibody (horseradish peroxidase conjugated), TRIZOL reagent, SuperScriptII Reverse Transcription Kit, Lipofectamine 2000 Transfection Reagent were from Invitrogen Biotechnology (Carlsbad, CA). SYBR Green PCR Master Mixture was from Applied Biosystems (Carlsbad, CA). 2D Clean up Kit, 2D Quant kit, 13 cm IPG strip (pH 3-10 NL), and dithiothreitol (DTT) were from GE Healthcare (Waukesha, WI).
Cell Culture and Drug Treatment
HepG2 cells (ATCC, Manassas, VA), grown in Dulbecco's Modified Eagle's Medium (DMEM, GIBCO, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, GIBCO, Carlsbad, CA) and 1% penicillin/streptomycin (P/S, GIBCO, Carlsbad, CA), were cultured at 37°C in an atmosphere containing 5% CO 2 .
Stock solution of oridonin (274.5 mM) was prepared in dimethyl sulfoxide (DMSO, Sigma, France). Aliquots were stored at -20°C. HepG2 cells were treated with various concentrations of oridonin for indicated durations. Control cells were treated with 0.1% DMSO.
Cell Viability Assay
HepG2 cells (5.0 × 10 3 cells per well) were seeded and grown in 96-well plates for 24 hours and then treated with various concentrations of oridonin. After a 24-hour incubation, 10 mL of 5 mg/mL MTT solution was added to each well and plates were incubated at 37°C for 4 hours. Following medium removal, 100 mL of DMSO was added to each well and plates were gently shaken for 5 minutes. Optical absorbance was determined at 570 nm with a microplate spectrophotometer (BD Bioscience, San Jose, CA). Absorbance obtained by vehicle-treated cells was rated as 100% of cell survival. Each treatment was performed in triplicate and each experiment was repeated 3 times.
Apoptosis Analysis by Flow Cytometry
Early and late phase apoptotic cells were monitored with Annexin V-FITC Apoptosis Detection Kit I. Cells were washed twice with cold PBS, resuspended in binding buffer, and incubated with FITC and PI staining solution following manufacturer's instructions. Samples of 10 000 stained cells were analyzed using a flow cytometer (BD Bioscience, San Jose, CA).
Phase-Contrast and Fluorescent Microscopic Imaging
HepG2 cells (40 × 10 4 ) grown on cover slips in 35-mm dishes were treated for 24 hours as indicated and then observed under a phase-contrast (Leica, Germany) microscope or a fluorescent microscope (Nikon, Japan) after DAPI (10 mg/mL) staining.
Proteomic Sample Preparation and 2-Dimensional Electrophoresis (2DE)
HepG2 cells treated with 40 mM oridonin for 24 hours were harvested by trypsinization, washed 3 times with isotonic buffer (10 mM Tris, 250 mM sucrose, pH 7.2) and lysed in a lysis buffer (8 M urea, 4% CHAPS, 40 mM DTT, and 0.5% pH3-10 NL IPG buffer) by gentle shaking for 60 minutes on ice. The extracts were centrifuged at 25 000g for 60 minutes at 4°C. Supernatants were purified with 2D Clean up Kit following manufacturer's instructions. Protein concentration of the purified samples was determined using 2D Quant kit. First dimension separation was performed using 13-cm IPG strip. Samples were diluted in rehydration solution (8 M urea, 2% CHAPS, 0.5% IPG buffer, 0.002% bromophenol blue, freshly added 0.28% dithiothreitol) to reach a final protein load of 100 mg (in 250 mL) per strip. IPG strips were actively rehydrated at 30 V for 12 hours then focused at 500 V for 2.5 hours, 1000 V for 0.5 hours, and then the voltage was increased to 8000 V gradually over the next 3 hours and maintained at 8000 V for 40 000 V h. Focused strips were equilibrated for 15 minutes in equilibration buffer (6 M urea, 75 mM Tris-HCl, pH 8.8, 29.3% glycerol, 2% SDS) with 1% (w/v) dithiothreitol (DTT, GE Healthcare, Waukesha, WI) freshly added to reduce electro endosmotic effects. This was followed by 15 minutes in the same equilibration buffer containing 2.5% IAA to remove excess DTT and to prevent streaking. The second dimension separation was carried out in 10% SDS-PAGE (20 mA/gel, 10 minutes; 25 mA/gel, 260 minutes).
Silver Staining and Image Analysis
Protein spots were visualized by silver staining as described previously. 13 The stained gels were scanned with LabScan 6.0 (GE Healthcare, Waukesha, WI) and data were analyzed with Progenesis SameSpots (Nonlinear Dynamics, UK). One image was chosen and allocated as the reference gel to align all other images in the experiment. Following manual alignment, spot detection, background subtraction, and normalization were performed. Spot volume, expressed relative to total spot density, was used to identify spots that differed significantly in normalized volume between control and test samples. In all cases, when statistical variance of the test/ control spot intensity ratio was within 95% (P < .05) the paired spots were considered to be significantly different.
Only those significantly and consistently upregulated or downregulated spots (>2 folds) or spots that appeared or disappeared after treatment in 3 independent experiments were selected for the in-gel digestion.
In-Gel Digestion and MALDI-TOF MS/MS Analysis
Protein spots were excised from gels and the in-gel digestion was performed as described previously. 14 The mass spectra were obtained using the Bruker AutoflexIII matrix-assisted laser desorption ionization time of flight (MALDI-TOF/TOF) Mass Spectrometer (Bruker Daltonics, Billerica, MA). Protein identification was performed automatically by searching the Swiss-Prot 55.3 database using the MASCOT 2.04 search engine (Matrix Science, UK). Database searches were carried out using the following parameters: type of search, MS/MS ion search; enzyme, trypsin; and allowance of one missed cleavage. Carbamidomethylation was selected as a fixed modification, and oxidation of methionine was allowed to be variable. The peptide and fragment mass tolerance were set at 50 ppm and 0.5 Da, respectively. The instrument was selected as MALDI-TOF/TOF. Proteins with probability-based MOWSE (molecular weight search) scores (P < .05) were considered to be positively identified.
Western Blot Analysis
Cells treated with 40 mM oridonin for indicated durations were collected and proteins were extracted with RIPA lysis buffer (50 mM Tris-Cl, 1% v/v NP-40, 0.35% w/v sodiumdeoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, pH 7.4) containing Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail. Protein concentration was determined by Bio-Rad Protein Assay. Thirty micrograms of individual protein samples were separated by SDS-PAGE and then electrotransferred onto the nitrocellulose membrane. Membranes were blocked for 30 minutes with 3% skim milk in TBST buffer composed of 50 mM Tris (pH 7.6), 150 mM NaCl, and 0.1% Tween-20 and incubated with primary antibodies overnight at 4°C followed by incubation with horseradish peroxidase-conjugated secondary antibodies. Protein signals were visualized by ECL detection reagents according to manufacturer's instruction.
Small Interfering RNA (siRNA) Transfection
RNA interference was used to silence a-CP1 gene expression. Transient gene silencing was attained by transfection of siRNA into cells using Lipofectamine 2000 transfection reagent according to the manufacturer's instructions. Briefly, HepG2 cells were grown in 6-well plates overnight and transiently transfected with 50 nM a-CP1 siRNA or control siRNA by using 5 mL Lipofectamine 2000. The transfection reagents/siRNA complex was diluted with DMEM (FBS and antibiotic free) to a total transfection volume of 2 mL. After incubation for 6 hours at 37°C, the medium was discarded and growth medium (DMEM medium with 10% FBS) was added. Cells were incubated at 37°C for a further 54 hours and then subjected to a 12-hour treatment with oridonin at 40 mM. The cells were then collected for verification of a-CP1 knockdown by real-time polymerase chain reaction (PCR) and for analyses of cell viability, and apoptosis by MTT assay and flow cytometry, respectively.
Real-Time Polymerase Chain Reaction
Cells were collected and total RNA was isolated using TRIZOL reagent according to the manufacture's protocol. Two micrograms of RNA was used for reverse transcription by oligo-dT using the SuperScriptII Reverse Transcription Kit. The real-time PCR primers of a-CP1 were designed as follows: sense 5´-aggtgaaaggctattgggcaagt-3´ and antisense 5´-ggatcatgggagaacagcagaaa-3´. To normalize the amounts of RNA in samples, a PCR reaction was also performed with primers of b-actin (sense 5´-gactacctcatgaagatc-3´ and anti-sense 5´-gatccacatctgctggaa-3´). Realtime PCR was performed in a total volume of 20 μL with 1 X Power SYBR Green PCR Master Mixture in the 7500 Fast Real-time PCR system (Applied Biosystems). All samples were run in triplicate.
Data Analysis
All results are expressed as the mean ± standard error of the mean (mean ± SEM). Differences between 2 groups were analyzed using the Student's t test.
Results
Oridonin Inhibited Cell Proliferation and Induced Apoptosis
MTT assay showed that treatment with oridonin for 24 hours resulted in a dose-dependent decrease in cell viability (Figure 2A ). The IC 50 value was determined as 40.4 mM from the dose-response curve with GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA). In the following assays, 40 mM oridonin was used.
To monitor the occurrence of apoptosis, flow cytometric analysis for the annexin V-FITC/PI-stained HepG2 cells was performed. Results showed that oridonin treatment for 24 hours induced significant apoptosis. Figure 2B shows the representative results of three independent experiments. Apoptosis rate was 34.9 ± 4.52% in oridonin-treated cells versus 4.27 ± 0.64% in control cells. Morphological changes in apoptotic cells were observed under a fluorescence microscope after DAPI staining. Typical apoptotic nucleus alterations (chromatin condensation, nuclear fragmentation, appearance of apoptotic bodies) were observed after oridonin treatment ( Figure 2C ).
Oridonin Caused Differential Expressions of Grp78 and a-CP1 in HepG2 Cells
We used a 2DE-based proteomic approach to identify proteins involved in oridonin activities in HepG2 cells. Cells were treated with oridonin for 24 hours at 40 mM. To ascertain reproducibility each treatment was repeated 3 times and each protein sample was analyzed by 2DE 3 times. Figure 3A shows the representative gel images. Proteins within the range of 15 to 225 kDa with isoelectric point (PI) between 3 and 10 were well separated. More than 800 spots were detected on each gel. Two protein spots of interest ( Figure 3B ) with changes of more than 2-fold in terms of volume intensity were cut from the gels, trypsin digested and analyzed by MALDI-TOF-MS/MS. The upregulated spot was identified as 78-kDa glucose-regulated protein precursor (Grp78/Bip, gene name GRP78) and the downregulated spot as Poly(rC)-binding protein 1 (a-CP1/hnRNP-E1, gene name PCBP1). The 2 proteins are listed in Table 1 , and their mass spectra are shown in Supplementary Materials online.
The expression changes of Grp78 and a-CP1 in response to oridonin treatment were confirmed by Western blotting (Figure 3C ). 
Oridonin Affected the Expression of ER Stress-Related Proteins in HepG2 Cells
Improper protein folding in the endoplasmic reticulum (ER), causes ER stress, and activates a signaling network called unfolded protein response (UPR). 15 Grp78, a master UPR regulator, plays a critical role in activating 3 UPR mediators, namely, PKR-like ER kinase (PERK), activating transcription factor 6 (ATF-6) and inositol-required enzyme 1 (IRE1), 16 which can induce the transcription of CAAT/ enhancer binding proptein homologous protein (CHOP). 17 Grp78 expression was found to be increased upon oridonin treatment; thus we speculate that oridonin may induce ER stress in HepG2 cells. To validate this hypothesis, Western blot analysis was applied to examine expression levels of IRE-1, ATF-6, PERK, and CHOP. As shown in Figure 4 , treatment with 40 mM oridonin time-dependently increased the expression of phosphorylated PERK (p-PERK) and CHOP, and decreased the expression of PERK, ATF-6, and IRE-1 in HepG2 cells. These data indicate that oridonin induces ER stress in HepG2 cells.
Transient Transfection of a-CP1 siRNA Reduced Cell Viability and Increased Apoptosis in HepG2 Cells
Downregulation of a-CP1 in oridonin-treated HepG2 cells was identified in our proteomics analysis. To characterize the role of a-CP1 in proliferation and apoptosis of cells treated with oridonin, we attempted to overexpress a-CP1 protein by transiently transfecting a pcDNA3.1-PCBP1 plasmid, but we failed in overexpressing the protein for unknown reasons (data not shown). Instead we used siRNA to knock down a-CP1. a-CP1 mRNA expression levels in cells treated with a siRNA specific to a-CP1 were significantly lower than those in control siRNA-treated cells 72 hours after siRNA transfection both in the presence and absence of 12-hour oridonin treatment ( Figure  5A ). Silencing of a-CP1 resulted in a significant decrease in cell viability and a more than 4-fold increase in baseline apoptosis. Furthermore, treatment with a-CP1 siRNA caused a significant reduction of cell viability and a greater than 2-fold increase in apoptosis in oridonin-treated cells ( Figures 5B and 5C) . These data suggest a role for a-CP1 in cell proliferation and apoptosis and suggest that downregulation of a-CP1 positively contributes to the antiproliferative and apoptotic effects of oridonin in HepG2 cells.
Discussion
Previous reports have shown that oridonin induces apoptosis in human hepatoma BEL-7402 and HepG2 cells by inhibiting telomerase activity and ROS generation. 9, 10 In this study, we identified differentially expressed proteins, Grp78 and a-CP1, in oridonin-treated HepG2 cells and demonstrated that ER stress and a-CP1 are potentially involved in the antiproliferative and apoptotic activities of oridonin in HepG2 cells.
To survive under ER stress, cells activate a self-protective mechanism against ER stress termed UPR, which involves the upregulation of genes encoding ER chaperone proteins. 18 The chaperone protein Grp78 is central to the coordinated activation of UPR. 19 We detected the upregulation of Grp78 upon oridonin treatment; thus we hypothesized that oridonin might induce ER stress in HepG2 cells. To address this, we examined the activation and expression status of PERK, ATF-6, IRE1, and CHOP in oridonin-treated HepG2 cells, because during ER stress, the ER stress transducer proteins PERK, ATF-6, and IRE1 will be activated and consequently CHOP transcription will be induced. 20 Our results showed that in response to oridonin treatment, PERK, ATF-6, and IRE1 were activated and CHOP protein expression was increased, suggesting that oridonin does activate ER stress in HepG2 cells. Generally, UPR is a self-protective mechanism that enhances the protein folding capacity of the ER to prevent aggregation of proteins, reduces the amount of new proteins loaded in the ER lumen to prevent further accumulation of unfolded proteins, and increases degradation of misfolded proteins in the ER. 21 However, persistent or overwhelming ER stress will lead to apoptosis via transcriptional induction of CHOP. 20 Based on our current observations, we are unable to tell whether ER stress is cytoprotective or pro-apoptotic in oridonin-treated HepG2 cells. Further investigations are needed to answer this question.
a-CP1 is a member of the heterogeneous nuclear ribonucleoproteins (hnRNP) family. Downregulation of a-CP1 was observed in HepG2 cells upon oridonin treatment. Using RNAi strategy, we demonstrated that inhibition of a-CP1 expression increased cell death and apoptosis in control and oridonin-treated cells, suggesting a role for a-CP1 in cell survival. Implicating a-CP1 in cell death suggests the importance of the traditional role a-CP1 plays in controlling cellular responses through c-Myc and Bag-1. a-CP1 has been shown to be able to stimulate the translation of c-Myc and Bc1-2-associated athanogene Bag-1. 22 Since the suppressions of c-Myc and Bag-1 are associated with apoptosis induction, [23] [24] [25] the downregulation of a-CP1 may be responsible for the apoptotic effect of oridonin in HepG2 cells by reducing c-Myc and Bag-1 protein expression; this possibility needs further investigation.
We, for the first time, discovered the upregulation of Grp78 in oridonin-treated cells, although its upregulation has been found in other agent-treated cancer cells. 26, 27 Knowing that Grp78 has a role in ER stress, we investigated ER stress status in oridonin-treated HepG2 cells. Results showed that oridonin treatment activated ER stress. a-CP1 is the other novel oridonin target identified in this study. Our siRNA experiments demonstrated the role of a-CP1 in cell growth and apoptosis for the first time. In summary, this work provides proteomic and functional evidence for the potential involvement of ER stress and a-CP1 in the antiproliferative and apoptotic activities of oridonin in HepG2 cells. Further investigations are merited to delineate the involvement of ER stress and a-CP1 in the anti-hepatocarcinoma activities of oridonin.
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